Lancet Publication Marks Important Advance in Influenza Prevention for Older Adults
Phase 3 study demonstrates benefits of the first influenza vaccine to combine three proven approaches to enhancing protection for older adults in a single vaccine.
MAIDENHEAD, United Kingdom, Sept. 11, 2026 /PRNewswire/ -- CSL Seqirus, a business of CSL (ASX: CSL; USOTC: CSLLY), today announced publication of pivotal Phase 3 study results for its...
Read more: Lancet Publication Marks Important Advance in Influenza Prevention for Older Adults




